Madrigal registers new Phase 1b trial testing resmetirom in MASH patients with HFpEF
Madrigal Pharmaceuticals filed a new study combining its MASH treatment with a heart failure indication, not yet recruiting.
Madrigal Pharmaceuticals posted one new trial registration this week.
- Madrigal registered "A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure With Preserved Ejection Fraction (HFpEF)" (NCT07830758), which is not yet recruiting1. The study will randomize participants 2:1 to resmetirom or placebo for 24 weeks1, with an estimated enrollment of 90 participants1 and a dosing scheme in which resmetirom dose will be based on actual body weight, at 80 mg once daily for participants weighing less than 100 kg and 100 mg once daily for those weighing 100 kg or more1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.